

December 7, 2012
Announcement no. 27

BioPorto completes cash issue, private placement

On December 3, 2012, the Board of Directors of BioPorto A/S decided to make use of its authorization under § 16b of the Company Articles to make a cash issue directed to a limited number of shareholders. The completion of the issue has today been approved by the Board.

The cash issue was fully subscribed and the Board has determined to issue a total of 2,000,000 new shares each with nominal value DKK 3.00, corresponding to a total nominal value of DKK 6,000,000.

The subscription price is 170, which equates to DKK 5.10 per share at a nominal value of DKK 3.00. The subscription price is the weighted average price of the share over the past six trading days preceding the Board's decision on December 3, 2012. The issue thus provides BioPorto with gross proceeds of DKK 10.2 million, from which transaction costs of DKK 0.6 million have to be subtracted to yield net proceeds of DKK 9.6 million.

The new shares equate to 4.4% of BioPorto's registered share capital before the capital increase, thus making the cash issue exempt from the obligation to publish a prospectus.

The new shares carry the same rights as existing shares. The new shares will be eligible for dividends as from the moment when they have been fully paid for and issued. The capital increase is expected to be registered with The Danish Business Authority on December 10, 2012. The new shares are expected to be admitted for listing on NASDAQ OMX Copenhagen as soon as possible. After registration of the 2,000,000 new shares each with nominal value DKK 3.00, BioPorto's total nominal share capital will amount to DKK 141,449,052, consisting of 47,149,684 shares each with nominal value DKK 3.00.

Proceeds and use of proceeds

The proceeds will be used to the daily operation of the company and the initiation of new clinical studies for the registration of The NGAL Test in the US. During the first quarter of 2013, BioPorto expects to make arrangements with a single major investor regarding additional funding in 2013 and 2014. In the coming years, significant activities need to be initiated, including clinical trials, in order to substantiate BioPorto's and BioPorto partner's marketing of The NGAL Test. With the agreement, the company is also provided funding for all current liabilities, including convertible debt.

Trading by the Board of Directors and Management

In the cash issue, the Company's Board of Directors and Management have subscribed shares, distributed as follows:

Name	Position	No. of shares	DKK
Carsten Lønfeldt	Chairman of the Board	8,000	38,760
Marianne Weile Nonboe	Board Member	9,000	40,800
Niels Tækker Foged	Board Member	7,600	45,900
Thea Olesen	CEO	4,400	22,440

For further information, please contact:

Thea Olesen, CEO
Christina Thomsen, Investor Relations
Telephone +45 4529 0000, e-mail investor@bioporto.com